Literature DB >> 24688146

Effects of lorglumide on growth and invasion of human pancreatic cancer cell line Mia PaCa-2 in vitro through the cholecystokinin-cholecystokinin-1 receptor pathway.

Jin Zhou1, Zi-Xiang Zhang1, De-Chun Li1.   

Abstract

BACKGROUND: Cholecystokinin (CCK) has been found to be a growth stimulant through its special receptor pathway, especially for gastrointestinal malignancies. Although the CCK-1 receptor has been shown to be highly expressed in resected human pancreatic cancer samples, its role is less clear.
OBJECTIVE: The aim of this in vitro study was to investigate the CCK-1 receptor expression and the function of the CCK-CCK-1 receptor pathway in the human pancreatic adenocarcinoma cell line, Mia PaCa-2.
METHODS: The expression of the CCK-1 receptor in Mia PaCa-2 cells was detected by reverse-transcriptase polymerase chain reaction and flow cytometry. CCK-1 receptor agonist CCK-8S (the major transmitter form of CCK) and antagonist lorglumide were cultured respectively with Mia PaCa-2. Three groups were created for this study: CCK-8S group (Mia PaCa-2 cells treated with CCK-8S), lorglumide group (Mia PaCa-2 cells treated with lorglumide), and the control group (Mia PaCa-2 cells alone). Investigators were blinded to group designation. 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry were used to detect the cell growth, cell cycle, and apoptosis. Apoptosis index rate was measured by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling. Cell invasion ability was observed by invasion assay. Expression of matrix metalloproteinase-2 (MMP-2) was measured by Western blotting.
RESULTS: Mia PaCa-2 cells were found to express the CCK-1 receptor. Compared with the control group (70.2% [1.5%]), CCK-8S was associated with significant mean (SD) cell proliferation (85.1% [1.7%]; P = 0.039), and the ratio in the S stage of the cell cycle increased significantly (50.5% [1.7%] vs 42.2% [1.4%]; P = 0.021). CCK-8S was also associated with increased Mia PaCa-2 cell invasion ability (123.8 [1.7] vs 102.1 [5.8]; P = 0.005 vs control). Compared with the control group, lorglumide was associated with significantly inhibited cell growth (52.1% [1.8%]; P = 0.002) and cell invasion (77.6% [1.2%]; P = 0.003). Lorglumide also induced G0/G1 cell cycle arrest and apoptosis (27.1% [3-5%] vs 3-7% [0.6%]; P = 0.003 vs control). The change of invasion ability appeared to be mediated by MMP-2 expression, which was upregulated by CCK-8S and downregulated by lorglumide.
CONCLUSION: The findings of this in vitro study suggest that CCK may exert a trophic action on the Mia PaCa-2 cell line, while lorglumide inhibited the cell growth and invasion.

Entities:  

Keywords:  CCK-1 receptor; MMP-2; apoptosis; cholecystokinin; pancreatic cancer

Year:  2010        PMID: 24688146      PMCID: PMC3969616          DOI: 10.1016/j.curtheres.2010.08.005

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  32 in total

1.  Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin.

Authors:  Cristina González-Puga; Ana García-Navarro; Germaine Escames; Josefa León; Manuel López-Cantarero; Eduardo Ros; Darío Acuña-Castroviejo
Journal:  J Pineal Res       Date:  2005-10       Impact factor: 13.007

Review 2.  Novel secondary hormonal therapy in advanced prostate cancer: an update.

Authors:  Eliezer M Van Allen; Charles J Ryan
Journal:  Curr Opin Urol       Date:  2009-05       Impact factor: 2.309

3.  CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.

Authors:  Berthold A Nock; Theodosia Maina; Martin Béhé; Anastasia Nikolopoulou; Martin Gotthardt; Jörg S Schmitt; Thomas M Behr; Helmut R Mäcke
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

4.  Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer.

Authors:  Zhi-Jie Cheng; Kaleeckal G Harikumar; Wei-Qun Ding; Eileen L Holicky; Laurence J Miller
Journal:  Cancer Lett       Date:  2005-05-10       Impact factor: 8.679

Review 5.  The neurohumoral control of pancreatic exocrine secretion.

Authors:  F P Brooks
Journal:  Am J Clin Nutr       Date:  1973-03       Impact factor: 7.045

6.  Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.

Authors:  M Määttä; Y Soini; A Liakka; H Autio-Harmainen
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

7.  Peripheral injection of CCK-8S induces Fos expression in the dorsomedial hypothalamic nucleus in rats.

Authors:  Peter Kobelt; Stephan Paulitsch; Miriam Goebel; Andreas Stengel; Marco Schmidtmann; Ivo R van der Voort; Johannes J Tebbe; Rüdiger W Veh; Burghard F Klapp; Bertram Wiedenmann; Yvette Taché; Hubert Mönnikes
Journal:  Brain Res       Date:  2006-09-26       Impact factor: 3.252

Review 8.  Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.

Authors:  Marc J Berna; Jose A Tapia; Veronica Sancho; Robert T Jensen
Journal:  Curr Opin Pharmacol       Date:  2007-11-09       Impact factor: 5.547

Review 9.  New therapeutic advances in the management of progressive thyroid cancer.

Authors:  Jennifer A Woyach; Manisha H Shah
Journal:  Endocr Relat Cancer       Date:  2009-02-13       Impact factor: 5.678

10.  Cholecystokinin-2 receptor modulates cell adhesion through beta 1-integrin in human pancreatic cancer cells.

Authors:  C Cayrol; P Clerc; C Bertrand; V Gigoux; G Portolan; D Fourmy; M Dufresne; C Seva
Journal:  Oncogene       Date:  2006-03-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.